prIME Rounds: Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma - priME Oncology

prIME Rounds: Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

Not a member of My prIME? Join now for instant access.

March 2016—Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) halted ongoing first-line trials of idelalisib in combination with other agents due to an increased risk of serious adverse events including death, mostly due to infections.

  • Information about the FDA’s announcement is available on the FDA Website
  • Information about the EMA’s announcement is available on the EMA Website

prIME Rounds: Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma

View Activity

Activity Overview

This CME-certified prIME Rounds in chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL) Webcast focuses on recent advances in therapy and management of patients with these diseases.

  • Ian W. Flinn, MD, PhDSarah Cannon Research Institute
    Nashville, Tennessee, United States
  • Ajay Gopal, MDUniversity of Washington and
    Fred Hutchinson Cancer Research Center
    Seattle, Washington, United States

Target Audience

This educational activity is designed for hematologists, oncologists, and other healthcare professionals involved in the management of patients with CLL and iNHL.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Discuss recent clinical trial data regarding the safety and efficacy of novel treatment options for CLL and iNHL
  • Employ best practices for treatment selection and integration of novel agents in patients with CLL and iNHL
  • Discuss strategies to identify and manage treatment-related adverse events to improve quality of life and outcomes in patients with CLL and NHL
  • Identify appropriate clinical trials in which to enroll patients with CLL and indolent NHL


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

View Activity


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This educational activity is supported by grant from Gilead Sciences, Inc.

Activity Date

November 9, 2015

November 9, 2016